Alzheimer’s Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Cholinesterase Inhibitors, N-Methyl D-Aspartate Antagonist, Combination Drugs, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region Forecast 2019-2030

Alzheimer’s Therapy market size was valued at US$ 4,211.8 million in 2023 and is poised to grow at a CAGR of 16.3% from 2024 to 2030. Alzheimer’s disease is a neurological disorder that causes the brain to shrink and brain cells to die. Alzheimer’s disease is the most common cause of dementia leads to the continuous decline in thought processes, social and behavioural skills that affect the ability of a person to function independently. The early symptoms of Alzheimer’s disease include forgetting recent events or conversations.

An Alzheimer diseased patient portal will have severe memory loss and lose the ability to carry out everyday tasks as the disease progresses. The rise in the prevalence of Alzheimer’s disease in emerging countries and developed countries is expected to drive market growth in the forecasted period. In addition, the increase in the occurrence of Alzheimer’s disease across the globe by the diagnosis of patients has boosted Alzheimer’s disease therapy. According to the Alzheimer’s Association, approximately 6 million people are living with Alzheimer’s in the USA and it can be expected to reach 13 Million by 2050.

Moreover, the availability of various drug classes for Alzheimer’s disease is expected to boost to growth of the Alzheimer’s disease market. The increase in several Alzheimer's disease cases thus increases the demand for Alzheimer’s therapy. Advancement in the treatment, and drug discovery techniques drives the demand for Alzheimer’s therapy across the globe. Rising investment in research and development of innovative drugs by the key pharmaceutical companies is expected to fuel the growth Alzheimer’s disease market. In addition, the presence of pipeline drugs in the clinical trial phase is expected to boost the growth of the Alzheimer’s market in a significant rate in the forecasted period. Geographically, the North America region held the major market share in 2022 and is expected to dominate the global market in the forecasted years.

Alzheimer’s Therapy Market Key Developments

• In October 2022, Cyclo Therapeutics Inc. commenced their phase II study of their pipeline drug ‘Trappsol Cyclo’.
• In January 2023, the U.S. Food and Drug Administration approved Eisai, Inc.’s Leqembi via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.